📰 ReutersReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 13:06:18时区推断·⟳ 抓取 13:10:30·⚡ 决策 07-28 13:13:06 +2m36s·91.4 天前
康诺亚-B与乐普生物合作ADC胃癌III期OS阳性且阿斯利康给出30亿至50亿美元峰值销售预期
本事件本身对康诺亚-B（02162.HK）与乐普生物（02157.HK）为明确正向：Sone-Ve/CMG901在晚期胃癌III期达到总生存期终点，且阿斯利康给出30亿至50亿美元峰值销售预期。
📄 原文Reuters↗ 原文
Hong Kong-listed Keymed Biosciences (2162.HK) said on Tuesday a late-stage trial of sonesitatug vedotin, a therapy tar…
不做 康诺亚-B（02162.HK）
同一CMG901胃癌III期OS阳性催化已在2026-07-27由本系统处理并生成过ENTER LONG决策，当前Reuters稿为重复扩散，不再重复建仓。
不做 乐普生物（02157.HK）
同一CMG901胃癌III期OS阳性催化已在2026-07-27由本系统处理并生成过ENTER LONG决策，当前Reuters稿为重复扩散，不再重复建仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 high · price-in 风险 high ↗
消息传播链
- 2026-07-27官方确认/否认AstraZeneca/公司公告声称一手 · 未核验阿斯利康公布Sone-Ve/CMG901全球III期胃癌研究达到OS终点，内部KB同日已有券商点评覆盖。
- 多篇券商点评在2026-07-27已解读该药OS阳性、PFS未达统计显著及30亿至50亿美元峰值销售预期。
- 路透转述康诺亚-B、乐普生物交易所披露及AZ合作信息，未提供足以区别于前一日已处理催化的新交易事实。市场反应:截至2026-07-28 05:11-05:12 UTC，康诺亚-B（02162.HK）报79.15港元跌3.83%，乐普生物（02157.HK）报4.63港元涨4.28%。
关键理由
- 本事件本身对康诺亚-B（02162.HK）与乐普生物（02157.HK）为明确正向：Sone-Ve/CMG901在晚期胃癌III期达到总生存期终点，且阿斯利康给出30亿至50亿美元峰值销售预期。
- 但已处理消息库显示同一具体催化在2026-07-27已生成过“值得做”决策，当前路透稿属于同一事件的后续转述/扩散，不应重复推卡。
- 商业化量级上，若30亿至50亿美元峰值销售由AZ商业化后按合作权益回流，理论弹性很大，但当前卡片边界被去重闸否决。
主要风险
- 去重后不再新建仓；若后续出现首次披露申报时间、监管受理或权益分成等新增事实，应按新事件重新研判。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-27 · 影响 weakens
反向因素是PFS未达统计学显著，但OS终点阳性与AZ峰值销售指引仍支持事件方向为利好；本次不做的核心原因是重复处理而非基本面证伪。
检索:康诺亚 乐普生物 CMG901 PFS 未达统计学显著 OS 阳性 风险 原文 ↗
工具调用 · 历史记录,结果未知(6 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
- search_case_library · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,329 字
Hong Kong-listed Keymed Biosciences (2162.HK) said on Tuesday a late-stage trial of sonesitatug vedotin, a therapy targeting treatment for advanced or metastatic gastric cancer, has achieved positive topline results.
The therapy is being developed by KYM Biosciences, a joint venture between Keymed and Lepu Biopharma (2157.HK), in collaboration with London-listed AstraZeneca (AZN.L).
Sonesitatug vedotin demonstrated a "highly clinically meaningful improvement" in overall survival compared to standard chemotherapy in its global Phase III clinical trial, Keymed said.
The company said that the drug met a primary endpoint of overall survival for third or later-line treatment, as well as the key secondary endpoint of overall survival in the trial population for second or later-line treatments.
However, the drug did not achieve statistical significance in its other primary goal of progression-free survival — the time a patient lives without the disease worsening — though it did show an improving trend, Lepu said.
The drug was well-tolerated with no new safety concerns, both Keymed and Lepu said in exchange filings.
Based on the positive clinical trial results, AstraZeneca has announced that the estimated peak sales for the product will be between $3.0 billion and $5.0 billion, Keymed said.
The therapy is being developed by KYM Biosciences, a joint venture between Keymed and Lepu Biopharma (2157.HK), in collaboration with London-listed AstraZeneca (AZN.L).
Sonesitatug vedotin demonstrated a "highly clinically meaningful improvement" in overall survival compared to standard chemotherapy in its global Phase III clinical trial, Keymed said.
The company said that the drug met a primary endpoint of overall survival for third or later-line treatment, as well as the key secondary endpoint of overall survival in the trial population for second or later-line treatments.
However, the drug did not achieve statistical significance in its other primary goal of progression-free survival — the time a patient lives without the disease worsening — though it did show an improving trend, Lepu said.
The drug was well-tolerated with no new safety concerns, both Keymed and Lepu said in exchange filings.
Based on the positive clinical trial results, AstraZeneca has announced that the estimated peak sales for the product will be between $3.0 billion and $5.0 billion, Keymed said.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。